^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    POLA2 (DNA Polymerase Alpha 2)

    i
    Other names: POLA2, DNA Polymerase Alpha 2, Accessory Subunit, DNA Polymerase Alpha 70 KDa Subunit, DNA Polymerase Alpha Subunit B, Polymerase (DNA Directed), Alpha 2 (70kD Subunit), Polymerase (DNA) Alpha 2, Accessory Subunit, FLJ21662, Polymerase (DNA Directed), Alpha 2, Accessory Subunit, Polymerase (DNA-Directed), Alpha (70kD)
    Associations

    News

    Trials
    8ms
    Identification of FANCG as a prognostic factor for prostate cancer. (PubMed, Eur J Med Res)
    This study suggests that FANCG likely plays a pivotal role in PCa progression. In addition, increased FANCG expression may serve as an indicator of poor disease-free survival and an adverse prognosis for PCa patients.
    Journal
    |
    POLD1 (DNA Polymerase Delta 1) • FANCG (FA Complementation Group G) • LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1) • MCM5 (Minichromosome Maintenance Complex Component 5) • MCM7 (Minichromosome Maintenance Complex Component 7) • POLA2 (DNA Polymerase Alpha 2)
    10ms
    A-to-I RNA edited POLA2 attains carcinogenesis in prostatic cancer by impeding immune infiltration and upregulating BTBD7. (PubMed, Discov Oncol)
    A-to-I RNA edited POLA2 attained carcinogenesis in PCa by impeding immune infiltration, fortifying glycolysis and upregulating BTBD7, indicating that edited POLA2 has the potential to become a tool for gene therapy.
    Journal
    |
    CD8 (cluster of differentiation 8) • ADAR (Adenosine Deaminase RNA Specific) • BTBD7 (BTB Domain Containing 7) • POLA2 (DNA Polymerase Alpha 2)
    11ms
    The identification and prediction of lung adenocarcinoma prognosis using a novel gene signature associated with DNA replication. (PubMed, Transl Cancer Res)
    An innovative signature related to DNA replication was found to be a good prognostic predictor of LUAD. Our findings may provide novel insights into the diagnosis and treatment of LUAD.
    Journal • Gene Signature • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • PD-L2 (Programmed Cell Death 1 Ligand 2) • POLD1 (DNA Polymerase Delta 1) • PCNA (Proliferating cell nuclear antigen) • POLD2 (DNA Polymerase Delta 2) • MCM4 (Minichromosome Maintenance Complex Component 4) • POLE4 (DNA Polymerase Epsilon 4 Accessory Subunit) • SIGLEC15 (Sialic Acid Binding Ig Like Lectin 15) • FEN1 (Flap Structure-Specific Endonuclease 1) • MCM2 (Minichromosome maintenance complex component 2) • MCM5 (Minichromosome Maintenance Complex Component 5) • MCM7 (Minichromosome Maintenance Complex Component 7) • RPA3 (Replication Protein A3) • MCM6 (Minichromosome Maintenance Complex Component 6) • POLA2 (DNA Polymerase Alpha 2)
    almost2years
    E2F-mediated POLA2 upregulation is correlated with macrophage infiltration and poor prognosis in hepatocellular carcinoma. (PubMed, Transl Cancer Res)
    POLA2 induced macrophage infiltration in the tumor microenvironment by upregulating the expression CSF1 and VEGFA expression. POLA2 is a novel diagnostic and prognostic biomarker of HCC with potential clinical value.
    Journal
    |
    CSF1 (Colony stimulating factor 1) • E2F1 (E2F transcription factor 1) • POLA2 (DNA Polymerase Alpha 2)
    |
    VEGFA expression • CSF1 expression
    almost2years
    Machine learning determines stemness associated with simple and basal-like canine mammary carcinomas. (PubMed, Heliyon)
    Finally, we suggested two promise stemness-associated targets in CMTs, POLA2 and APEX1, especially in simple carcinomas. Thus, our work elucidates stemness as a potential mechanism behind the aggressiveness and development of canine mammary tumors, especially in simple carcinomas, describing evidence of a promising strategy to target this disease.
    Journal • Machine learning
    |
    APEX1 (Apurinic/Apyrimidinic Endodeoxyribonuclease 1) • POLA2 (DNA Polymerase Alpha 2)
    over2years
    The Biological Function of POLA2 in Hepatocellular Carcinoma. (PubMed, Comb Chem High Throughput Screen)
    Our study demonstrated POLA2's importance in HCC development and progression and its potential role as a biomarker for disease progression on multiple levels. POLA2 has an important role in regulating the cell cycle and cell proliferation. By interfering with the cell cycle and proliferation, HCC cell growth is inhibited. Furthermore, POLA2 expression was significantly associated with immune infiltration. POLA2 may play a role in HCC immunotherapy based on its correlation with several immune cell types' genetic markers. The findings of this study are expected to lead to new anticancer strategies for HCC.
    Journal • IO biomarker
    |
    POLA2 (DNA Polymerase Alpha 2)
    over2years
    Circ-POLA2-mediated miR-138-5p/SEMA4C axis affects colon cancer cell activities. (PubMed, Acta Biochim Pol)
    Circ-POLA2 knockdown caused the blockade for cell activities, but this effect was alleviated by miR-138-5p inhibition or SEMA4C overexpression. Overall, circ-POLA2 is tumorigenic for CC through miR-138-5p/SEMA4C axis, which may provide a promising molecular target for CC therapy.
    Journal
    |
    MIR138 (MicroRNA 138) • POLA2 (DNA Polymerase Alpha 2)